GSK Confirms Guidance and Then Declines to Answer the Only Question That Mattered

A tidy 5% quarter, a new CEO who promises to stop burying bad news — and a four-monthly HIV dataset the entire sell side asked about three times and did not get

GSK · Earnings Call · 2026-10-28

The market is arguing about data centers; GSK is arguing about pharmacokinetics

Scroll the global theme tape this quarter and you find a market obsessed with AI data centers, tariff refunds and Fed policy — and, tellingly, the data-center trade is now a 90-day decliner after a spectacular year. GSK touches almost none of it. Its keywords are company-unique: non-small-cell lung cancer, surface antigen, different studies. That insulation is the point. In a tape where the crowded factor is unwinding, GSK's quarter is a closed-loop story about its own pipeline execution — which makes the one thing management would not explain considerably more interesting than the headline. Because the headline is boring-good: sales up 5% to £8.9bn, core operating profit up 5%, core EPS up just 1%, cash generation £7.4bn year-to-date and the 17p quarterly dividend intact. Full-year guidance was "reconfirmed," with sales and core operating profit both expected in the upper half of the range. Nothing to see. Except that EPS growth is guided to the low half of the range, in the same breath.

Three launches, one J-code, and a lot of muscle memory

Commercially, this was the quarter GSK finally had receipts on the specialty pivot. Nina Mojas took the launch inventory in sequence. Blenrep is approved in 52 markets and is now the second-line market leader in the UK on NICE-approved regimens; in the US, repeat prescribers account for roughly a third of sales. Exdensur did £27m, with US new prescribers up 68% and new patient starts up 74% including free first doses — a direct consequence of the J-code arriving 1 July and the ASP document landing 1 October. "Every week since then has been the highest week of sales for Exdensur one after another." Nucala grew 18% on COPD and GSK now claims over 90% share of the global MenB market. The genuinely new item is Hibsago — bepirovirsen — the first finite-treatment functional cure for chronic hepatitis B, approved in the US and Japan and priced at roughly £50,000 in Japan against just over £100,000 in the US. It is the freshest high-momentum keyword on the company's own list (Hibsago spiked hardest of any GSK term this quarter). The debate is ALT elevation and thrombocytopenia monitoring: frequent blood draws in the first 12 weeks, a home self-injection pack of four doses, and physicians "mentally gating" the first quarter before reassessing. Tony Wood reframed the flares as signal rather than noise — more than half of functional-cure patients had one — and promised 48-week durability data at AASLD. There is no competition until 2031 outside China. That is a real asset; it is also an asset whose adoption curve depends on how many hepatologists want to run a monitoring clinic.

The £300 million question, unanswered three times

Then the call turned. James Gordon, Michael Leuchten and Graham Parry each asked, in escalating specificity, about EXTEND — the PK bridging study for four-monthly cabotegravir PrEP — where the data is in-house, steady state was reached only weeks ago, and the analysis is not finished. What they wanted to know is whether the same formulation powers CUATRO, the four-monthly treatment efficacy study, and therefore whether a PK miss bleeds into the HIV treatment franchise that carries the company through the dolutegravir loss of exclusivity. David Redfern's answer was that these are "very different studies" — a PK bridging study versus an efficacy study — and that "we are very confident in the formulation that we have got. I will probably leave it at that." Tony Wood added: "I just want to underscore, we see no read-through to the treatment portfolio." Graham Parry pointed out that CUATRO uses the same formulation and asked, reasonably, why a PK or tolerability problem would not travel. Luke Miels' response was to decline to "front-run discussions with a regulator."

We are going to call things as we see them. We are not going to park crap on page 41 of a press release and hope none of you notice it. So, we will tell you as much as we can.
Luke Miels, Chief Executive Officer · 2026-10-28

The tension is not that management stonewalled — it is that this is precisely the promise they made six months ago. In February, Miels said: "If it's on track, you'll hear about it. If it's not, we'll call it out." And in October 2025, Deborah Waterhouse described a Q4M trial delay as one-off and insisted "this is a clinical trial supply delay is not related to efficacy or tolerability concerns at all, and we remain committed to 2027 file and 2028 launch." Four-monthly is now the thing that has quietly slipped from a clean timeline to an unexplained analysis. That is a change of state, and the market was told about it in the passive voice.

The financials the launches have to carry

Julie Brown's section is where the tension resolves into arithmetic. R&D grew 22% as GSK doubled phase III starts from 10 to 22 in a single year — an extraordinary acceleration, and the reason EPS grew 1% while operating profit grew 5%. The Accelerate Growth restructuring charge has already been revised up: "We originally guided GBP 0.7 billion. We are expecting now charges in the order of GBP 1 billion." Interest costs rise to £700–750m this year including £160m for Nuvalent, and £900m–£1bn next year. And 2027 carries identifiable, quantified headwinds: Trelegy's IRA-negotiated price of $175 per 30 days, a 73% discount to the 2024 list price; Breo alongside it; and the Biktarvy royalty step-down in October 2027 at roughly £70m a quarter. The offset has to come from SG&A leverage and mix, and Brown was careful: R&D will keep growing ahead of sales, "not to the extent of Q3." Meanwhile Shingrix was propped up by a US inventory build worth about 2 percentage points of global growth, with China still a destocking story — the fourth consecutive call on which China destocking has been the explanatory device. So the shape of the story is clear. GSK has a genuinely impressive launch machine and a pipeline that has been accelerated beyond anything in its recent history — naive patients in asthma and COPD, first-in-class lung cancer assets, a functional cure for hepatitis B. But the near-term numbers are being held together by mix and cost discipline while R&D spend runs hot, a $10bn acquisition digests, and the long-acting HIV franchise — the thing that has to bridge the dolutegravir cliff — has one unexplained dataset sitting between it and the market. That is not a quarter to sell. It is a quarter to press on. And the three analysts who did press got the same non-answer, which is itself information: when a management team promising radical transparency declines to characterise a PK result it already holds, the market should assume the analysis is harder than the framing suggests until told otherwise. The next scheduled opportunity is a regulatory update before year-end.